ID 1074 - Lactobacillus paracasei 8700:2 (DSM 13434, 240HI)

PL: Lactobacillus paracasei 8700:2 (DSM 13434, 240HI)
EN: Lactobacillus paracasei 8700:2 (DSM 13434, 240HI)
Pdf: Lactobacillus paracasei 8700:2

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claim is Lactobacillus paracasei 8700:2 (DSM 13434, also as 240HI). The genotypic identification and characterisation of the strain Lactobacillus paracasei 8700:2 (DSM 13434) by different molecular methods was reported (Antonsson and Molin, 2002; Vasquez et al., 2005). In addition, analysis of the genome of this microorganism is openly available (Draft-assembly status, accession nº NZ_ABQV00000000). The Panel notes that a culture collection number from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany), DSM 13434, is provided. In the DSMZ, which is a non-public International Depositary Authority under the Budapest Treaty, cultures can be deposited in a restricted-access collection as Patent deposits.
The Panel considers that the food constituent, Lactobacillus paracasei 8700:2 (DSM 13434, 240HI), which is the subject of the health claim, is sufficiently characterised.

2. Znaczenie oświadczenia dla zdrowia człowieka

The claimed effect is “strengthens the immune system” and “establishment of lactobacilli and beneficial changes in the microflora”. The Panel assumes that the target population is the general population.
The Panel considers that “strengthens the immune system” is not sufficiently defined
The numbers/proportions of bacterial groups that would constitute a “beneficial change in intestinal microflora” have not been established. Increasing the number of any groups of bacteria is not in itself considered as beneficial. The Panel considers that no evidence has been provided that the claimed
effect “establishment of lactobacilli and beneficial changes in the microflora” is beneficial to human health.
The Panel considers that “beneficial changes in the microflora” in the context of decreasing potentially pathogenic intestinal microorganisms might be beneficial to human health.

3. Naukowe uzasadnienia wpływu na zdrowie człowieka - Zmniejszenie ilość potencjalnie patogennych bakterii jelitowych

Eight references were cited to substantiate the claimed effect.
The references included a paper from the European Conference on Probiotics (EUPROBIO) in 2005, describing differential effects on the innate and acquired cellular immune system by intake of different lactobacilli in human volunteers (Rask et al., 2005). One reference with incomplete citation related to “probiotic” use for common cold prevention was not accessible to the Panel after every reasonable effort was made to retrieve it. The Panel considers that these references did not provide any scientific data that could be used to substantiate the claimed effect.
Two rat's studies (Osman et al., 2004 and 2005) investigated effects of Lactobacillus paracasei on dextran sulphate sodium induced-colitis and on D-galactose-induced liver injury. These references did not provide any scientific data that could be used to substantiate the claimed effect. Another publication (Hutt et al., 2006) described an in vitro study on the relative antagonistic activity of Lactobacillus paracasei according to different methods, and showed intermediate antagonistic activity against Helicobacter pylori. The Panel considers that these studies provide limited evidence to support the claimed effect in humans.
The remaining references referred to the use of Lactobacillus as adjunct cultures and the effect of “probiotic” strains in experimental autoimmune encephalomyelitis and are not related to the claimed effect.
The Panel notes that none of the references provided evidence for a relationship between the consumption of Lactobacillus paracasei 8700:2 (DSM 13434, 240HI) and the claimed effect in humans.
The Panel concludes that a cause and effect relationship has not been established between consumption of Lactobacillus paracasei 8700:2 (DSM 13434, 240HI) and decreasing potentially pathogenic intestinal microorganisms.

Warunki i możliwe ograniczenia stosowania oświadczenia

At least 109 cfu/day